Nextech 'Smacs' TetraLogic with additional $6 million for cancer drug program
This article was originally published in Scrip
Executive Summary
With the help of a new $6 million investment from Zurich, Switzerland-based Nextech, TetraLogic Pharmaceuticals has now raised $43 million in the past year, giving the biotech the funds it needs to complete its Phase IIa program of its experimental mitochondrial-derived activator of caspases (Smac) mimetic compound TL32711 in solid tumors and initiate studies of the drug in hematological cancers in the upcoming months.